Total
0
Shares
XORTX Therapeutics - CEO, Allen Davidoff.
CEO, Allen Davidoff.
Source: Richmond Club.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • XORTX Therapeutics (XRX) has received approval to list its common shares on the TSXV effective as of the open of market on November 4 under the symbol XRTX
  • Listing on the TSXV will increase the company’s visibility and access to domestic and institutional investors
  • XORTX has submitted a request to voluntarily delist its common shares from the CSE
  • XORTX Therapeutics Inc. is a biotechnology company working to create new therapeutics for kidney disease
  • XORTX Therapeutics Inc. (XRX) opened trading at C$3.42 per share

XORTX Therapeutics (XRX) has received approval to list its common shares on the TSXV effective as of November 4, 2021.

The company’s common shares will be listed under the share symbol XRTX.

Dr. Allen Davidoff, XORTX’s President and CEO stated,

“Listing on the TSXV is another significant milestone for the company. This listing will further increase the company’s visibility and access to domestic and institutional investors.”

XORTX has submitted a request to voluntarily delist its common shares from the CSE. The delisting is expected to be effective on November 4.

Shareholders are not required to exchange their share certificates or take any other action in connection with the TSXV listing, as there will be no change in the trading symbol or CUSIP for the common shares.

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development. 

XORTX Therapeutics Inc. (XRX) opened trading at C$3.42 per share.

More From The Market Herald
LexaGene - CEO, Dr. Jack Regan.

" LexaGene (TSXV:LXG) closes multiple MiQLab sales

LexaGene (LXG) has received purchase orders from Kuma Veterinary Clinic and the Emergency Veterinary Services of Roanoke.
The Market Herald Video

" FSD Pharma (CSE:HUGE) demonstrates positive effects of Lucid-MS in treating MS in pre-clinical models

FSD Pharma (HUGE) is sharing pre-clinical data demonstrating the potentially disease-modifying effects of its lead drug candidate Lucid-MS.
The Market Herald Video

" Adastra Holdings (CSE:XTRX) reports record third-quarter results

Adastra Holdings (XTRX) has filed its consolidated financial statements and related MD&A for the three and nine months ended September 30, 2021, and 2020.